Genetic gateways to COVID‐19 infection: Implications for risk, severity, and outcomes

The dynamics, such as transmission, spatial epidemiology, and clinical course of Coronavirus Disease‐2019 (COVID‐19) have emerged as the most intriguing features and remain incompletely understood. The genetic landscape of an individual in particular, and a population in general seems to play a pivotal role in shaping the above COVID‐19 dynamics. Considering the implications of host genes in the entry and replication of SARS‐CoV‐2 and in mounting the host immune response, it appears that multiple genes might be crucially involved in the above processes. Herein, we propose three potentially important genetic gateways to COVID‐19 infection; these could explain at least in part the discrepancies of its spread, severity, and mortality. The variations within Angiotensin‐converting enzyme 2 (ACE2) gene might constitute the first genetic gateway, influencing the spatial transmission dynamics of COVID‐19. The Human Leukocyte Antigen locus, a master regulator of immunity against infection seems to be crucial in influencing susceptibility and severity of COVID‐19 and can be the second genetic gateway. The genes regulating Toll‐like receptor and complement pathways and subsequently cytokine storm induced exaggerated inflammatory pathways seem to underlie the severity of COVID‐19, and such genes might represent the third genetic gateway. Host‐pathogen interaction is a complex event and some additional genes might also contribute to the dynamics of COVID‐19. Overall, these three genetic gateways proposed here might be the critical host determinants governing the risk, severity, and outcome of COVID‐19. Genetic variations within these gateways could be key in influencing geographical discrepancies of COVID‐19.

[1]  Joseph K. Pickrell,et al.  Evolutionary Dynamics of Human Toll-Like Receptors and Their Different Contributions to Host Defense , 2009, PLoS genetics.

[2]  Yan Zhao,et al.  The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China , 2020, Clinical Immunology.

[3]  Frederic A. Fellouse,et al.  Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility , 2020, bioRxiv.

[4]  A. Mungall,et al.  Characterization of clustered MHC-linked olfactory receptor genes in human and mouse. , 2001, Genome research.

[5]  C. Chakraborty,et al.  Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach , 2020, Journal of medical virology.

[6]  F. Wang,et al.  Association of HLA-A, B, DRB1 alleles and haplotypes with HIV-1 infection in Chongqing, China , 2009, BMC infectious diseases.

[7]  Xiaosheng Wang,et al.  Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues , 2020, Infectious Diseases of Poverty.

[8]  P. Tiwari,et al.  HLA‐A*02 repertoires in three defined population groups from North and Central India: Punjabi Khatries, Kashmiri Brahmins and Sahariya Tribe , 2019, HLA.

[9]  D. Harlan,et al.  Ethnicity Greatly Influences Cytokine Gene Polymorphism Distribution , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  C. Yancy,et al.  COVID-19 and African Americans. , 2020, JAMA.

[11]  M. Katze,et al.  Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection , 2015, mBio.

[12]  N. Eriksson,et al.  Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections , 2016, Nature Communications.

[13]  Richard L. Doty,et al.  Smell dysfunction: a biomarker for COVID‐19 , 2020, International forum of allergy & rhinology.

[14]  Zhaofeng Chen,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[15]  M. Bhatia,et al.  ACE and ACE2 in inflammation: a tale of two enzymes. , 2014, Inflammation & allergy drug targets.

[16]  J. Jan,et al.  HLA-A∗0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins , 2006, Biochemical and Biophysical Research Communications.

[17]  R. D'Agostino,et al.  Genetic and non-genetic correlates of vitamins K and D , 2009, European Journal of Clinical Nutrition.

[18]  M. Banerjee,et al.  Pro-inflammatory cytokines and their epistatic interactions in genetic susceptibility to schizophrenia , 2016, Journal of Neuroinflammation.

[19]  Merlin C. Thomas,et al.  Genetic Ace2 Deficiency Accentuates Vascular Inflammation and Atherosclerosis in the ApoE Knockout Mouse , 2010, Circulation research.

[20]  Elisa Lo Monaco,et al.  A Single Bottleneck in HLA-C Assembly* , 2008, Journal of Biological Chemistry.

[21]  M. Rivas,et al.  Initial Review and Analysis of COVID-19 Host Genetics and Associated Phenotypes , 2020 .

[22]  Yen-Ju Chen,et al.  Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. , 2011, Viral immunology.

[23]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[24]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[25]  Lisa E. Gralinski,et al.  Allelic Variation in the Toll-Like Receptor Adaptor Protein Ticam2 Contributes to SARS-Coronavirus Pathogenesis in Mice , 2017, G3: Genes, Genomes, Genetics.

[26]  Katie M. Campbell,et al.  Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approach , 2020, bioRxiv.

[27]  Shengqing Wan,et al.  Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations , 2020, Cell Discovery.

[28]  Wei Chen,et al.  Extensive Acute Lower Extremity Arterial Thrombosis: A Major Thrombus Formation Caused by COVID-19 , 2020, medRxiv.

[29]  Proton Rahman,et al.  Genetic variability of human angiotensin‐converting enzyme 2 (hACE2) among various ethnic populations , 2020, bioRxiv.

[30]  T. Morrison,et al.  Complement and viral pathogenesis , 2011, Virology.

[31]  J. Luban.  SARS-CoV-2 , 2020 .

[32]  Chloe H. Lee,et al.  In silico identification of vaccine targets for 2019-nCoV , 2020, F1000Research.

[33]  W. Grant,et al.  Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths , 2020, Nutrients.

[34]  R. D. Mittal,et al.  Ethnicity greatly influences the interleukin-1 gene cluster(IL-1b promoter, exon-5 and IL-1Ra) polymorphisms: a pilot study of a north Indian population. , 2005, Asian Pacific journal of cancer prevention : APJCP.

[35]  G Thomson,et al.  Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. , 2004, Tissue antigens.

[36]  P. Xiong,et al.  Lack of association between HLA‐A, ‐B and ‐DRB1 alleles and the development of SARS: a cohort of 95 SARS‐recovered individuals in a population of Guangdong, southern China , 2008, International journal of immunogenetics.

[37]  Rui Ji,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[38]  H. Koohy,et al.  In silico identification of vaccine targets for 2019-nCoV. , 2020, F1000Research.

[39]  K. Garcia,et al.  The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands , 2017, Cell Reports.

[40]  R. Carlier,et al.  Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study , 2020, European Archives of Oto-Rhino-Laryngology.

[41]  H. Bischoff-Ferrari,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency; a position statement of the European Calcified Tissue Society. , 2019, European journal of endocrinology.

[42]  Q. Lepiller,et al.  Features of anosmia in COVID-19 , 2020, Médecine et Maladies Infectieuses.

[43]  Wenfeng Qian,et al.  Asians and Other Races Express Similar Levels of and Share the Same Genetic Polymorphisms of the SARS-CoV-2 Cell-Entry Receptor , 2020 .

[44]  Abhinav Nellore,et al.  Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Journal of Virology.

[45]  M. Satake,et al.  Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population , 2009, Human Immunology.

[46]  Keiko Ozato,et al.  Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. , 2002, BioTechniques.

[47]  G. Fey,et al.  Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor , 2004, Biochemical and Biophysical Research Communications.

[48]  Lisa E. Gralinski,et al.  Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis , 2018, mBio.

[49]  M. Milinski,et al.  Major histocompatibility complex peptide ligands as olfactory cues in human body odour assessment , 2013, Proceedings of the Royal Society B: Biological Sciences.

[50]  Syed Faraz Ahmed,et al.  Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies , 2020, Viruses.

[51]  Mushtaq Hussain,et al.  Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike protein , 2020, Journal of medical virology.

[52]  Ruifu Yang,et al.  Identification of an HLA-A*0201–restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein , 2004, Blood.

[53]  D. Harlan,et al.  Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. , 2001, Transplantation.

[54]  M. Ho,et al.  Epidemiological and Genetic Correlates of Severe Acute Respiratory Syndrome Coronavirus Infection in the Hospital with the Highest Nosocomial Infection Rate in Taiwan in 2003 , 2006, Journal of Clinical Microbiology.

[55]  W. Liu,et al.  IL-12 RB1 Genetic Variants Contribute to Human Susceptibility to Severe Acute Respiratory Syndrome Infection among Chinese , 2008, PloS one.

[56]  Man Wai Ng,et al.  The interferon gamma gene polymorphism +874 A/T is associated with severe acute respiratory syndrome , 2006, BMC infectious diseases.

[57]  D Middleton,et al.  Analysis of the distribution of HLA-B alleles in populations from five continents. , 2000, Human immunology.

[58]  D Middleton,et al.  Analysis of the distribution of HLA-A alleles in populations from five continents. , 2000, Human immunology.

[59]  Mayda Gursel,et al.  Is global BCG vaccination‐induced trained immunity relevant to the progression of SARS‐CoV‐2 pandemic? , 2020, Allergy.

[60]  David Burgner,et al.  HLA and Infectious Diseases , 2009, Clinical Microbiology Reviews.

[61]  J. Sung,et al.  Association of Human-Leukocyte-Antigen Class I (B*0703) and Class II (DRB1*0301) Genotypes with Susceptibility and Resistance to the Development of Severe Acute Respiratory Syndrome , 2004, The Journal of infectious diseases.

[62]  Sean K. Maden,et al.  Human leukocyte antigen susceptibility map for SARS-CoV-2 , 2020, medRxiv.

[63]  C. Fang,et al.  Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. , 2009, Blood.

[64]  Noam Sobel,et al.  Individual olfactory perception reveals meaningful nonolfactory genetic information , 2015, Proceedings of the National Academy of Sciences.

[65]  Andrew R. Jones,et al.  Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..

[66]  Jason A. Tetro,et al.  Is COVID-19 receiving ADE from other coronaviruses? , 2020, Microbes and Infection.

[67]  A. Kimura,et al.  HLA linked with leprosy in southern China: HLA-linked resistance alleles to leprosy. , 1999, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[68]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[69]  Fang Li,et al.  Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.

[70]  A. Sanchez‐Mazas.  HLA studies in the context of coronavirus outbreaks. , 2020, Swiss medical weekly.

[71]  Ming Zhao.  Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies , 2020, International Journal of Antimicrobial Agents.

[72]  Matthias Klein,et al.  Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients , 2020, medRxiv.

[73]  J. Loo,et al.  Association of HLA class I with severe acute respiratory syndrome coronavirus infection , 2003, BMC Medical Genetics.

[74]  M. Grant,et al.  Loss of Angiotensin-Converting Enzyme-2 Exacerbates Diabetic Cardiovascular Complications and Leads to Systolic and Vascular Dysfunction: A Critical Role of the Angiotensin II/AT1 Receptor Axis , 2012, Circulation research.

[75]  S. Beck,et al.  MHC-linked olfactory receptor loci exhibit polymorphism and contribute to extended HLA/OR-haplotypes. , 2000, Genome research.

[76]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[77]  E. García-Latorre,et al.  Prediction of SARS-CoV2 spike protein epitopes reveals HLA-associated susceptibility , 2020 .